|
Quidel to Present at 24th Annual Piper Jaffray Healthcare Conference
SAN DIEGO, CA, Nov 20, 2012 (MARKETWIRE via COMTEX) --
Quidel Corporation (NASDAQ: QDEL), a leading provider of diagnostic
testing solutions and cellular-based virology assays, announced today
that it will present at the 24th Annual Piper Jaffray Healthcare
Conference to be held at The New York Palace hotel in New York, NY on
Tuesday, November 27, 2012.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present that day at 9:30 a.m.
Eastern time (6:30 a.m. Pacific time) with a question and answer
session scheduled immediately following the presentation. During the
presentation, the company will discuss business and financial
developments and trends. The company's statements may contain or
constitute material information that has not been previously
disclosed.
A live webcast and audio archive of the presentation will be
available via the Investor Relations section of the company's Web
site at www.quidel.com. Participants should allow approximately five
to ten minutes prior to the presentation's start time to visit the
site and download any streaming media software needed to listen to
the Internet webcast. A replay of the webcast will also be available
on the company's Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of
people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
QuickVue(R), D3(R) Direct Detection and Thyretain(R) leading brand
names, as well as under the new Sofia(R) brand, Quidel's products aid
in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory syncytial
virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult
blood. Quidel's research and development engine is also developing a
continuum of diagnostic solutions from advanced lateral-flow and
direct fluorescent antibody to molecular diagnostic tests to further
improve the quality of healthcare in physicians' offices and hospital
and reference laboratories. For more information about Quidel's
comprehensive product portfolio, visit quidel.com and Diagnostic
Hybrids at dhiusa.com.
Quidel Contact:
Quidel Corporation
Randy Steward
Chief Financial Officer
(858) 552-7931
Media and Investors Contact:
Quidel Corporation
Ruben Argueta
(858) 646-8023
Email Contact
SOURCE: Quidel
http://www2.marketwire.com/mw/emailprcntct id=3B0235CC724DB61A
[ InfoTech Spotlight's Homepage ]
|